Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell’s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing. For more information, please visit http://www.xcellbio.com/.
Location: United States, California, San Francisco
Employees: 11-50
Phone: +1 415-937-0321
Total raised: $39.5M
Founded date: 2012
Investors 2
| Date | Name | Website |
| 10.03.2024 | RONA Holdi... | ronaholdin... |
| - | Avego | avego.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.01.2022 | Series B | $27.5M | - |
| 22.02.2017 | Series A | $12M | - |
Mentions in press and media 7
| Date | Title | Description |
| 19.01.2022 | Xcellbio Closes $27.5M Series B Financing | SAN FRANCISCO, CA, Xcell Biosciences, a developer of cell and gene therapies, announced $27.5 million in Series B financing led by Casdin Capital. >> Click here for more funding data on Xcellbio >> To export Xcellbio funding... |
| 19.01.2022 | Dynamk Capital Joins World-Class Syndicate of LS Investors Participating in Xcellbio’s $27.5 Series B Round | Xcell Biosciences, Inc. (“Xcellbio”), a leading developer of innovative technologies and platforms designed to further the research, development, and manufacturing of cell and gene therapies, announced $27.5 million in Series B financing le... |
| 19.01.2022 | Xcellbio Announces $27.5 Million Series B Financing | Xcell Biosciences, Inc. (“Xcellbio”), a leading developer of innovative technologies and platforms designed to further the research, development, and manufacturing of cell and gene therapies, today announced $27.5 million in Series B financ... |
| 04.01.2018 | Xcell Biosciences Announces New Emphasis Towards Immunotherapy Markets and Expands Leadership Team | Company Welcomes Janette Phi as Chief Operations Officer SAN FRANCISCO–(BUSINESS WIRE)–January 4, 2018– Xcell Biosciences announced today that it has expanded its development and commercial efforts around new market opportunities in immunot... |
| 16.02.2017 | Term Sheet — Thursday, February 16 | SNAP CRACKLE DROP Snap goes low: Either Snap is setting itself up for a big pop, or the company’s underwriters are nervous about how the market reacted to Snap’s slowing growth and major losses. Paid Content How can you protect what you can... |
| 16.02.2017 | Xcell Biosciences Receives $12M Series A Funding Round | Xcell Biosciences, a San Francisco, CA-based provider of an advanced primary cell culturing platform, closed a $12m Series A private equity financing round. The round was led by HBM Genomics with participation from all major existing invest... |
| 16.02.2017 | Xcell Biosciences Announces $12 Million Series A Funding Round | Investors include HBM Genomics and Viking Global Investors Company to expand commercial efforts for its proprietary primary cell culture platform across cancer, stem cell, immunology, cell manufacturing, cell therapy, and regenerative medic... |